The Medicare Payment Advisory Commission (MedPAC) convened a session to discuss ways to lower Medicare spending on Part B drugs. Staff presented three sets of policy options to Commissioners that addressed spending incentives, including: (1) first-in-class drugs and ways to cap payment rates for high-cost products; (2) reference pricing strategies for drugs with therapeutic alternatives; and (3) ways to modify… (Testa, January 18, 2023) #Biosimilars, #Drug Pricing